Navigation Links
Skinvisible Appoints New Vice President of Business Development & Marketing
Date:6/11/2008

Strategic Plan for Invisicare Strengthens

LAS VEGAS, June 11 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI), the developers of Invisicare, a patented polymer delivery system that brings unique therapeutic and marketing benefits to topically applied products, announces a new executive appointment. Doreen McMorran will serve as Vice President of Business Development and Marketing, performing an integral role as the Company continues to grow in terms of new licensees, new products, new alliances as well as expansion into areas outside of dermatology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO)

Ms. McMorran will focus on driving business growth through new licensee acquisition for Skinvisible's formulated products and technology. She will contribute to the on-going strategic direction of the Company and will be charged with identifying and growing the Company's business opportunities. The goal is to identify new revenue streams through the penetration of markets complementary and additional to the Company's prime market of dermatology and to enhance the global reach of the Company.

"We have expanded our sales and marketing efforts in order to maintain our strategic business development momentum on a global scale," stated Mr. Terry Howlett, President and CEO of Skinvisible. "With Ms. McMorran's contacts in the dermatology industry and having her drive our strategic sales and marketing efforts, we are confident that she will successfully lead a focused and strategic sales effort that meets our long term growth objectives. We are excited to have Ms. McMorran on board as we continue to position Invisicare as the #1 choice for companies seeking enhanced features for their products and critical product life cycle management."

Ms. McMorran brings to the Company almost 20 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing. She has spent the last six years selling to international dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis and Graceway, to name a few, providing medical education for physicians and consumers about dermatology conditions, products and treatments. Ms. McMorran, who holds a Bachelor of Commerce (Honors) degree, spent six years in the pharmaceutical industry with Astra Pharma. Additionally she has held senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing and operations.

About Invisicare(R)

Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare(R). Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See: http://www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See: http://www.skinvisible.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 30, 2008)

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc.

Phone: 702-433-7154

Email: info@skinvisible.com


'/>"/>
SOURCE Skinvisible, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Skinvisible Signs Licensing Agreement for Two Acne Formulations
2. Skinvisible Appoints New Board Member
3. Skinvisible Announces Licensing Agreement for Adapalene
4. Skinvisible Signs Marketing Agreement for India
5. Skinvisible Appoints Dr. George Korkos to Its Advisory Board
6. Skinvisible to Present at Merriman Curhan Ford & Co.s Investor Summit 2007
7. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
8. amfAR Appoints Dr. Annette Sohn as Vice President of Global Initiatives
9. Disc Motion Technologies Appoints Industry Veteran as New CEO
10. Setaram Inc. Appoints New CEO/VP
11. VA Secretary Appoints Panel of National Suicide Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... in many scientific laboratories. The assembly protocols involve many repetitive steps and often ... for automation, which enables the high-throughput needed, and results in a lower error ...
(Date:3/29/2017)... , ... March 29, 2017 , ... Hamlin Dental Group, ... is now offering laser dental treatments. Dental lasers are safe and effective options, and ... patients’ options and can improve the overall quality of care. , Dr. Hamid Reza ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Gastrointestinal Oncology™ (SOGO™), a specialized continuing medical education conference for clinicians who manage ... Intercontinental Time Square, New York. , The program will be led by ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... AvePoint ... seventh North American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 ... attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017 Neurim Pharmaceuticals ("Neurim") ... obtain exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... treat sleep disorders in children with Autism Spectrum Disorders (ASD) and ... approved for children. The collaboration with Exeltis will help ...
(Date:3/29/2017)... , March 29, 2017 ... Sectra (STO: SECT B) announces that ... install Sectra PACS in their healthcare enterprise. The ... Epic EMR, will enable access and sharing of ... Additionally, UPHS and Sectra will enter into a ...
(Date:3/28/2017)...  Las Vegas ophthalmology practice, Center For Sight, announced ... Dublin ), an implant that shunts ... intraocular pressure in patients with moderate to severe glaucoma. ... glaucoma that can lead to progressive optic nerve damage ... untreated. According to the National Eye Institute, ...
Breaking Medicine Technology: